Transcenta Holding Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
80
- Stock Symbol
-
06628
- Investments
-
2
- Share Price
-
$0.08
- (As of Friday Closing)
Transcenta Holding General Information
Description
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and process development, uniquely positioned to advance high-impact biologic innovations with commercial potential. Its main assets include Osemitamab (TST001), an anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development, and Blosozumab (TST002), an anti-Sclerostin monoclonal antibody. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and, geographically, operates in the Chinese mainland, the United States of America, and other regions, with the Chinese Mainland deriving the majority of revenue.
Contact Information
Website
www.transcenta.comCorporate Office
- Room B6-501, Bio-Nano Park, 218 Xinghu Street
- Suzhou Industrial Park
- Suzhou, Jiangsu 215123
- China
Corporate Office
- Room B6-501, Bio-Nano Park, 218 Xinghu Street
- Suzhou Industrial Park
- Suzhou, Jiangsu 215123
- China
Transcenta Holding Stock Performance
As of 13-Nov-2026, Transcenta Holding’s stock price is $0.08. Its current market cap is $36.2M with 427M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.08 | $0.09 | $0.07 - $0.39 | $36.2M | 427M | 800K | -$0.05 |
Transcenta Holding Financials Summary
As of 30-Jun-2026, Transcenta Holding has a trailing 12-month revenue of $4.05M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 80,043 | 138,821 | 33,891 | 155,952 |
| Revenue | 4,047 | 1,034 | 1,569 | 7,611 |
| EBITDA | (15,156) | (20,851) | (32,477) | (57,522) |
| Net Income | (23,050) | (28,329) | (40,456) | (65,382) |
| Total Assets | 131,227 | 132,181 | 164,419 | 238,876 |
| Total Debt | 20,280 | 18,046 | 34,329 | 57,787 |
Transcenta Holding Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Transcenta Holding Comparisons
Industry
Financing
Details
Transcenta Holding Competitors (3)
One of Transcenta Holding’s 3 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
Transcenta Holding Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Transcenta Holding Patents
Transcenta Holding Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025130921-A1 | Formulation comprising anti-claudin18.2 antibody | Inactive | 19-Dec-2023 | ||
| AU-2024284935-A1 | Combination therapies involving claudin 18.2 antagonists for treatment of cancer | Pending | 03-Jun-2023 | ||
| AU-2024284935-A9 | Combination therapies involving claudin 18.2 antagonists for treatment of cancer | Pending | 03-Jun-2023 | ||
| EP-4720132-A1 | Combination therapies involving claudin 18.2 antagonists for treatment of cancer | Pending | 03-Jun-2023 | ||
| US-20260265370-A1 | Combination therapies involving claudin 18.2 antagonists for treatment of cancer | Pending | 03-Jun-2023 | C07K16/28 |
Transcenta Holding Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Transcenta Holding Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Transcenta Holding Acquisitions (2)
Transcenta Holding’s most recent deal was a Merger of Equals with Hangzhou Just Biotherapeutics. The deal was made on 02-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Hangzhou Just Biotherapeutics | 02-Jan-2019 | Merger of Equals | Drug Discovery | ||
| MabSpace Biosciences | 02-Jan-2019 | Merger of Equals | Drug Discovery |
Transcenta Holding ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Transcenta Holding Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| MabSpace Biosciences | Suzhou, China | 2012 | |
| Transcenta Holding (CDMO Manufacturing Assets in Hangzhou, China) | Hangzhou, China |
Transcenta Holding FAQs
-
When was Transcenta Holding founded?
Transcenta Holding was founded in 2013.
-
Where is Transcenta Holding headquartered?
Transcenta Holding is headquartered in Suzhou, China.
-
What is the size of Transcenta Holding?
Transcenta Holding has 80 total employees.
-
What industry is Transcenta Holding in?
Transcenta Holding’s primary industry is Biotechnology.
-
Is Transcenta Holding a private or public company?
Transcenta Holding is a Public company.
-
What is Transcenta Holding’s stock symbol?
The ticker symbol for Transcenta Holding is 06628.
-
What is the current stock price of Transcenta Holding?
As of 13-Nov-2026 the stock price of Transcenta Holding is $0.08.
-
What is the current market cap of Transcenta Holding?
The current market capitalization of Transcenta Holding is $36.2M.
-
What is Transcenta Holding’s current revenue?
The trailing twelve month revenue for Transcenta Holding is $4.05M.
-
Who are Transcenta Holding’s competitors?
Astellas Pharma, Gilead, and Amgen are competitors of Transcenta Holding.
-
What is Transcenta Holding’s annual earnings per share (EPS)?
Transcenta Holding’s EPS for 12 months was -$0.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
